The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized Patients
Abstract
BACKGROUND: Data suggest that higher doses of vancomycin can increase the risk of nephrotoxicity. No study has been undertaken to determine the pharmacodynamic index (ie, the area under the curve [AUC] or the trough value) that best describes the relationship between vancomycin exposure and onset of nephrotoxicity. METHODS: A retrospective study was conducted among patients who received vancomycin for a suspected or proven gram-positive infection during the period from 1 January 2005 through 31 December 2006 at Albany Medical Center Hospital. Patients were included in our study if they (1) were > or =18 years old, (2) had an absolute neutrophil count of > or =1000 cells/mm(3), (3) received vancomycin for >48 h, (4) had 1 vancomycin trough level collected within 96 h of vancomycin therapy, and (5) had a baseline serum creatinine level of <2.0 mg/dL. Patients were excluded if they (1) had a diagnosis of cystic fibrosis, (2) received intravenous contrast dye within 7 days of starting vancomycin or during therapy, or (3) required vasopressor support during therapy. Demographics, comorbid conditions, and treatment data were collected. The highest observed vancomycin trough value within 96 h of initiation of vancomycin therapy and the estimated vancomycin AUC were analyzed as measures of vancomycin exposure. The vancomycin AUC value from 0 to 24 h at steady state (in units of mg x h/L) for each patient was estimated by use of the maximum a posteriori probability Bayesian procedure in ADAPT II. Nephrotoxicity was defined as an increase in serum creatinine level of 0.5 mg/dL or 50%, whichever was greater, following initiation of vancomycin therapy. Logistic and Cox proportional hazards regression models identified the vancomycin pharmacodynamic index that best describes the relationship between vancomycin exposure and toxicity. RESULTS: During the study period, 166 patients met the inclusion criteria. Both initial vancomycin trough values and 0-24-h at steady state AUC values were associated with nephrotoxicity in the bivariate analyses. However, the vancomycin trough value, modeled as a continuous variable, was the only vancomycin exposure variable associated with nephrotoxicity in the multivariate analyses. CONCLUSIONS: The results indicate that a vancomycin exposure-toxicity response relationship exists. The vancomycin trough value is the pharmacodynamic index that best describes this association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Self-citationDaptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Self-citationHidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
Self-citationRecursive Partitioning in the Health Sciences
Zhang, H., & Singer, B. (1999) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3027-2 · Cited by 451
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981
Farber, B. F., & Moellering, R. C. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.1.138 · Cited by 432
Jeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.014 · Cited by 334
Initial Low‐Dose Gentamicin for Staphylococcus aureus Bacteremia and Endocarditis Is Nephrotoxic
Cosgrove, S. E., Vigliani, G. A., Campion, M., Fowler, Jr., Abrutyn, E., Corey, G. R., Levine, D. P., Rupp, M. E., Chambers, H. F., Karchmer, A. W., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597031 · Cited by 309
Stryjewski, M. E., Graham, D. R., Wilson, S. E., O’Riordan, W., Young, D., Lentnek, A., Ross, D. P., Fowler, V. G., Hopkins, A., Friedland, H. D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587896 · Cited by 289
Vancomycin: A 50-Year Reassessment
Moellering, R. C. (2006) · Clinical Infectious Diseases · doi:10.1086/491708 · Cited by 275
Noel, G. J., Bush, K., Bagchi, P., Ianus, J., & Strauss, R. S. (2008) · Clinical Infectious Diseases · doi:10.1086/526527 · Cited by 270
Vancomycin pharmacokinetics in patients with various degrees of renal function
Rodvold, K. A., Blum, R. A., Fischer, J. H., Zokufa, H. Z., Rotschafer, J. C., Crossley, K. B., & Riff, L. J. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.6.848 · Cited by 249
Self-citationLodise, T. P., Lomaestro, B. M., & Drusano, G. L. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.9.1320 · Cited by 243
Self-citationSerum Vancomycin Concentrations: Reappraisal of Their Clinical Value
Cantu, T. G., Yamanaka-Yuen, N. A., & Lietman, P. S. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.4.533 · Cited by 230
Ingram, P. R., Lye, D. C., Tambyah, P. A., Goh, W. P., Tam, V. H., & Fisher, D. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn080 · Cited by 163
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
Rybak, M. J., Albrecht, L. M., Berman, J. R., Warbasse, L. H., & Svensson, C. K. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.5.792 · Cited by 139
Cimino, M. A., Rotstein, C., Slaughter, R. L., & Emrich, L. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90947-8 · Cited by 128
Editorial: Monitoring Serum Vancomycin Levels: Climbing the Mountain Because It Is There?
Moellering, R. C. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.4.544 · Cited by 123
Elting, L. S., Rubenstein, E. B., Kurtin, D., Rolston, K. V. I., Fangtang, J. T., Martin, C. G., RAAD, I. I., Whimbey, E. E., Manzullo, E. F., & Bodey, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2597::aid-cncr27>3.0.co;2-l · Cited by 109
Mild Nephrotoxicity Associated With Vancomycin Use
Downs, N. J. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390080053013 · Cited by 102
King, D. W., & Smith, M. A. (2004) · Toxicology in Vitro · doi:10.1016/j.tiv.2004.03.013 · Cited by 97
Protective Effects of Different Antioxidants and Amrinone on Vancomycin‐Induced Nephrotoxicity
Çelik, İ., Cihangiroğlu, M., İlhan, N., Akpolat, N., & Akbulut, H. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_153.x · Cited by 92
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Snydman, D. R. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70050-6 · Cited by 87
Çetin, H., Olgar, Ş., Öktem, F., et al. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04695.x · Cited by 81
Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits
Toyoguchi, T., Takahashi, S., Hosoya, J., Nakagawa, Y., & Watanabe, H. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1985 · Cited by 50
Effects of vancomycin on renal function in rats
Aronoff, G. R., Sloan, R. S., Dinwiddie, C. B., Glant, M. D., Fineberg, N. S., & Luft, F. C. (1981) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.19.2.306 · Cited by 48
Moyec, L. L., Racine, S. X., Toumelin, P. L., Adnet, F., Larue, V., Cohen, Y., Leroux, Y., Cupa, M., & Hantz, E. (2002) · Critical Care Medicine · doi:10.1097/00003246-200206000-00013 · Cited by 44
Protective Effect of Inactive Ingredients against Nephrotoxicity of Vancomycin Hydrochloride in Rats
Hodoshima, N., Nakano, Y., Izumi, M., Mitomi, N., Nakamura, Y., Aoki, M., Gyobu, A., Shibasaki, S., & Kurosawa, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.68 · Cited by 31
Cited by
Methicillin-resistant Staphylococcus aureus
Lee, A. S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.33 · Cited by 1,556
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Self-citationvan Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
Self-citationWunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., Kunkel, M. J., Baruch, A., McGee, W. T., Reisman, A., & Chastre, J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir895 · Cited by 570
Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463
Metadata
- Authors
- Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08-15
- Volume
- 49
- Issue
- 4
- Pages
- 507-514
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2158657903
- Cited by
- 554
- References
- 34
- FWCI
- 23.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.